What is ALZUMAb Injection used for?

Alzumab 25mg Injection is a medicine used for treatment of psoriasis. It affects certain cells of the immune system to reduce inflammation.

What is ALZUMAb?

ALZUMAb (drug name itolizumab) is a “humanized anti-CD6 monoclonal antibody” for adults with active moderate to severe psoriasis. It has a different mechanism of action than the biologics available in the US, Europe, and Japan. It’s only available in India, where it launched in 2013.

What are the side effects of tocilizumab?

Common side effects of Actemra include:

  • runny or stuffy nose,
  • sinus pain,
  • sore throat,
  • headache,
  • dizziness,
  • itching,
  • mild stomach cramps, or.
  • urinary tract infection (UTI).

What kind of drug is tocilizumab?

Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.

Does CoQ10 help anxiety?

CoQ10 is well established as a powerful antioxidant. More recent research appears to show that this antioxidant benefit may also help improve symptoms of mood disorders.

Does tocilizumab lower your immune system?

Tocilizumab affects your immune system and may affect healing. If you are on the shot, the medicine can cause itching or redness near the injection site. If this happens, the discomfort should be mild.

What do you need to know about Biocon’s Itolizumab?

Key things to know about Biocon’s Itolizumab: 1. Itolizumab will be used only for the treatment of patients with moderate to severe COVID-19 symptoms. 2.

How much does Alzumab cost per vial in India?

Additionally, patients stayed in remission for longer than they did from other treatment options. The drug is priced at a moderate $122 ($7,500 rupees) per vial, which is far lower than the many thousands of dollars that comparable biologic drugs cost in the U.S.

How is the drug ALZUMAb used to treat psoriasis?

The drug targets the CD6 surface receptor, binding to it and blocking activation of T cells in inflammatory environments within the body. The drug targets Th17 helper T cells, which were only discovered within the last six years and have been implicated in an array of autoimmune diseases.